Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Monte Rosa Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$18.24

+1.2 (+7.02%)

C 42Pipeline Score Overvalued Biotech · Commercial
Market Cap
1.59 B
EPS
-1.63
P/E Ratio
-
Value Trade
15.54 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    4.21 M

  • R&D Expenses

    44.07 M

  • Operating CF

    -37.37 M

  • Total Assets

    736.43 M

  • Total Liabilities

    214.51 M

  • Equity

    521.92 M

  • D/E Ratio

    12,345

1.9 %
Week
-11.81 %
1 Month
-0.58 %
3 Month
39.85 %
6 Month
-14.5 %
5 Year
-14.5 %
All Time
Cash Data
Healthy

  • Cash Position

    666.22 M

  • Monthly Burn

    12.46 M

  • Runway

    52.4 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 7, 2026
Overview
Volume
1.09 M
52 Week Range
3.90 - 25.77
% held by Insiders
30.39 %
% held by Institutions
82.74 %
Enterprise Value
961.90 M
Total Shares
65.15 M
Short %
32.45 %
Float Shares
49.32 M
Company Description
HQ: 321 HARRISON AVENUE, BOSTON, M...
Employees:161
https://www.monterosatx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 1 data readout example
MRT-8102 inflammatory diseases driven by the NLRP3 inflammasome
Phase 1
—
Small Molecules
Immunology
MRT-8102 inflammatory diseases driven by the NLRP3 inflammasome
Phase 1
—
Small Molecules
Immunology
MRT-8102 inflammatory diseases driven by the NLRP3 inflammasome
Phase 1
—
Small Molecules
Immunology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C42
Pipeline Score
$204M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.4x
rNPV / MCap
Top 57%
Micro Cap
(rank 390 of 905)
Percentile Rank
Monte Rosa Therapeutics, Inc. carries a moderate pipeline score (42/100), with $510M risk-adjusted pipeline value, led by MRT-2359 in NSCLC (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
MRT-2359
Small molecule		NSCLCPhase 1NCT0554626810% $294M ACTIVE NOT_RECRUITING 174 FAST C (40) Nov 1, 2027MODERATE_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
MRT-8102
inflammatory conditions,cardiovascular disease,pericarditis,atherosclerotic cardiovascular disease
Phase 1
2025-07-22
MRT-8102
inflammatory conditions,cardiovascular disease,pericarditis,atherosclerotic cardiovascular disease
Phase 1
2025-07-22
MRT-8102
inflammatory conditions,cardiovascular disease,pericarditis,atherosclerotic cardiovascular disease
Phase 1
2025-07-22
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in GLUE
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
GLUE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GLUE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GLUE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
GLUE Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
GLUE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Monte Rosa Therapeutics, Inc. (GLUE) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How GLUE ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Prostate Cancer #27 of 53 PHASE 1 MRT-2359
MRK AZN PFE
$25.12B 0.84 FOLLOWER
Breast Cancer #37 of 94 PHASE 1 MRT-2359
MRK AZN GILD
$10.85B 0.84 FOLLOWER
Lymphoma #38 of 69 PHASE 1 MRT-2359
REGN LLY MRK
$8.52B 0.84 FOLLOWER
Lung Cancer #44 of 79 PHASE 1 MRT-2359
MRK GILD AMGN
$28.1B 0.84 FOLLOWER
Non-Small Cell Lung Cancer #48 of 88 PHASE 1 MRT-2359
MRK AMGN AZN
$28.1B 0.84 FOLLOWER